383 related articles for article (PubMed ID: 29661510)
1. CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts.
Adam D; Bilodeau C; Sognigbé L; Maillé É; Ruffin M; Brochiero E
J Cyst Fibros; 2018 Nov; 17(6):705-714. PubMed ID: 29661510
[TBL] [Abstract][Full Text] [Related]
2. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
3. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
[TBL] [Abstract][Full Text] [Related]
4. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
5. Anti-Infectives Restore ORKAMBI
Laselva O; Stone TA; Bear CE; Deber CM
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092967
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
[TBL] [Abstract][Full Text] [Related]
7. Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.
Barnaby R; Koeppen K; Nymon A; Hampton TH; Berwin B; Ashare A; Stanton BA
Am J Physiol Lung Cell Mol Physiol; 2018 Mar; 314(3):L432-L438. PubMed ID: 29146575
[TBL] [Abstract][Full Text] [Related]
8. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
9. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
10. Quorum Sensing Down-Regulation Counteracts the Negative Impact of
Maillé É; Ruffin M; Adam D; Messaoud H; Lafayette SL; McKay G; Nguyen D; Brochiero E
Front Cell Infect Microbiol; 2017; 7():470. PubMed ID: 29177135
[TBL] [Abstract][Full Text] [Related]
11. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
[TBL] [Abstract][Full Text] [Related]
12. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
Stanton BA; Coutermarsh B; Barnaby R; Hogan D
PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
[TBL] [Abstract][Full Text] [Related]
13. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
14. In utero and postnatal ivacaftor/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets.
Evans IA; Sun X; Liang B; Vegter AR; Guo L; Lynch TJ; Zhang Y; Zhang Y; Yi Y; Yang Y; Feng Z; Park SY; Shonka A; McCumber H; Qi L; Wu P; Liu G; Lacina A; Wang K; Gibson-Corley KN; Meyerholz DK; Limoli DH; Rosen BH; Yan Z; Bartels DJ; Engelhardt JF
JCI Insight; 2024 Apr; 9(8):. PubMed ID: 38646935
[TBL] [Abstract][Full Text] [Related]
15. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
[TBL] [Abstract][Full Text] [Related]
16. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
17. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
18. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
19. Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR.
Matos AM; Gomes-Duarte A; Faria M; Barros P; Jordan P; Amaral MD; Matos P
Sci Rep; 2018 Aug; 8(1):13026. PubMed ID: 30158635
[TBL] [Abstract][Full Text] [Related]
20. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
